Radioisotope Life Sciences (RLS), a U.S.-based nuclear pharmacy network, recently appointed Glenn Sullivan, PhD, as the company's director of regulatory affairs.
In his new role, Sullivan will ensure that the company meets regulatory compliance on the local, state, and federal levels as RLS expands its network of 31 radiopharmacies. He will also support research and PET initiatives.
Sullivan has over 25 years of experience in regulatory affairs. Previously, he held such roles with Cardinal Health, Nuclear & Precision Health Solutions, Ann & Robert H. Lurie Children's Hospital of Chicago, Rush Presbyterian St. Luke's Medical Center, and Amersham/Medi-Physics.